Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orlistat and Intensive Weight Management for Blood Uric Acid Control in Obese Gout Patients
NCT07326839Not yet recruiting
- Start
- Dec 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of orlistat in gout and obesity (2 arms). Primary endpoint: Rate of patients achieving target serum uric acid levels (<360 μmol/L) at 24 weeks. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
orlistat
03
Conditions
goutobesity
Beyond the preview
Go deeper on NCT07326839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07326839.